Drug lookup | Fillwise

ONDANSETRON HYDROCHLORIDE

All products: not a benefit

Other products in the same Health Canada class (A04A, A04AA) — coverage varies; not interchangeable

Granisetron (Kytril): limited Use 326, 454, Not a benefit
Netupitant + palonosetron (Akynzeo): limited Use 561, 562
Ondansetron (Zofran): not a benefit
Nabilone (Cesamet): general benefit, Not a benefit
Aprepitant (Emend Tri-Pack): limited Use 452, 453

Zofran · DIN 02229639 · 4mg/5mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-14 — choose a marketed DIN from the same-category list.Discontinued 2017-03-14 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-14 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-03-14 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

1 brand, same coverage

Zofran · DIN 02229639 Manufacturer: Novartis Pharma Canada Inc.; listing date 1997-08-28 Health Canada: Cancelled post market since 2017-03-14 · brand ZOFRAN · ATC A04AA01 ONDANSETRON · form Solution · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4 MG/5ML · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Zofran: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47565 · Verify on the e-Formulary ↗ (DIN 02229639)

Source record

DIN 02229639: Zofran Raw flags: notABenefit=Y, sec3=Y Item: 562200025; group id 671; item number 1664; lccId 00102; manufacturer id NOV Source form: O/L; strength: 4mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229639 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47565

Interchangeable products

Apo-Ondansetron · DIN 02291967 · $0.7952 Jamp Ondansetron · DIN 02490617 · $0.7952 Mint-Ondansetron Solution · DIN 02524090 · $0.7952

Shortage status: discontinued (2022-10-01, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229639

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2017-03-14 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22

Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS Adults (18-64 years of age) pms-ONDANSETRON (ondansetron tablets) is indicated for: • the prevention of nausea and vomiting associated with mildly and moderately emetogenic chemotherapy, and radiotherapy. • the maintenance of antiemesis following intravenous doses of ondansetron used for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin. • the prevention of post-operative nausea and vomiting. 1.1 Pediatrics (<18 years of age) Prevention of Nausea and Vomiting Associated with Mildly and Moderately Emetogenic Chemotherapy • Pediatrics (4-12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ondansetron in pediatric patients 4-12 years of age has been established. Therefore, Health Canada has authorized an indication for pediatric use. (see 4.2 Recommended Dose and Dosage Adjustment). • Pediatrics (<4 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for the use of pms-ONDANSETRON in children less than 4 years of age. Prevention of Nausea and Vomiting Associat… https://pdf.hres.ca/dpd_pm/00077211.PDF PM date: April 19, 2006 Source product: PMS-ONDANSETRON; DIN 02258188; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Zofran · DIN 02229639 Shortage status: discontinued (2022-10-01, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229639

Check this DIN again

Other review policies

For Zofran: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026